| Biomarker ID | 1178 |
| PMID | 23896625 |
| Year | 2013 |
| Biomarker | SLCO2B1 rs12422149 (GG allele) |
| Biomarker Basis | Mutation Based |
| Biomolecule | Mutation |
| Source | Blood |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | HR: [0.589 (95% CI: 0.37–0.95)] |
| Effect on Pathways | Pathways include: Transport of organic anions, Transport of vitamins, nucleosides, and related molecules, SLC-mediated transmembrane transport, Oncostatin M, Transmembrane transport of small molecules |
| Experiment | Time to Progression |
| Type of Biomarker | Prognostic |
| Cohort | 87 patients with Prostate Cancer were included in the study. Of the 87 patients, 76 progressed to CRPC and 53 died during the median follow-up duration of 39.5 months. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p =0.028 |
| Method Used | PCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |